Loading...

CTMX CYTOMX THERAPEUTICS INC Investments/Divestments 8-K Filing

CYTM

CTMX

CYTOMX THERAPEUTICS INC

(CTMX)

2023 8-K

Financial Results

Clinical Trial Update

Financial Statements

Equity Offerings

Equity Offerings

Data Announcement

Financial Results

Management Change

Workforce Reduction

Q3 Financial Results

Financial Results

Appointment of CFO

Amendment to Certificate of...

Other Special Situation

Financial Results

Appointment of Director and...

Financial Results

Financial Results

Transition Agreement with A...

Financial Results

Equity Offerings

Financial Results

Financial Results Announcement

Liquidity Concern at Silico...

Restatement of Financial St...

Collaboration Agreement

External Links:

CytomX Therapeutics regains exclusive rights to develop CX-2029 through a Transition Agreement with AbbVie, with royalty obligations and potential future milestones to be paid to Seattle Genetics.

AI Assistant

CYTOMX THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.